Cohance Lifesciences Ltd.

₹443.35

-8.2 (-1.8%)

COHANCE Share Price

Pharmaceuticals & Biotechnology

As on September 9, 2026

SectorHealthcare

IndustryPharmaceuticals & Biotechnology

Basic IndustryPharmaceuticals

Market Cap₹ 17,379 Cr

P/E Ratio94.64

Dividend YieldN/A

Trendline Performance

We are partnered with TradingView, a global leader in charting and market analysis. Access real-time stock data, explore the powerful Stock Screener , and uncover insights with multiple tools designed for traders.

Unlock Stock of the Month

T&C*

Technicals

Indicators	Value	Signal
5-DMA	452.39	Bearish
10-DMA	454.01	Bearish
20-DMA	453.34	Bearish
50-DMA	444.55	Bearish
100-DMA	439.55	Bullish
200-DMA	424.49	Bullish

Historical Performance

1 Year

-56.5%

3 Years

-14.5%

5 Years

-17.2%

10 Years

N/A

Shareholding Pattern

Values Analysis

Loading chart...

Profit & Loss

Below figures are in Rs. Crores

Particulars	Mar-2026	Mar-2025	Mar-2024	Mar-2023	Mar-2022
Net Sales	22,686	26,085	10,513	13,403	13,202
Total Expenditure	18,416	18,114	6,455	7,662	7,385
Other Income	341	692	619	464	924
Operating Profit	4,611	8,663	4,677	6,205	6,741
Interest	372	411	74	128	85
Depreciation	1,873	1,668	546	480	391
Profit Before Tax	2,070	6,426	4,057	5,597	6,676
Consolidated Net Profit	1,792	4,873	3,003	4,113	4,538
Adjusted EPS	5	19	12	16	18

Compounded Sales Growth

10 Years:43.1

5 Years:17.6

3 Years:11.1

TTM:-2.8

Compounded Profit Growth

10 Years:10.4

5 Years:-13.1

3 Years:-15.3

TTM:-18.1

Stock Price CAGR

10 Years:N/A

5 Years:-3.7

3 Years:-5.1

TTM:-55.2

Return on Equity

10 Years:N/A

5 Years:17.8

3 Years:11.8

last year:4.7

Quarterly Results

Below figures are in Rs. Crores

Particulars	Sep-2024	Dec-2024	Mar-2025	Jul-2025	Sep-2025
Sales	1,70,754	1,35,936	1,28,552	1,22,189	1,05,161
Expenses	63,042	56,557	52,457	45,459	34,856
Operating Profit	1,07,712	79,379	76,096	76,730	70,304
OPM %	63%	58%	59%	63%	67%
Other Income	33,912	31,759	27,333	24,879	18,947
Interest	77,780	58,584	59,248	62,137	53,713
Depreciation	2,345	1,681	1,385	1,277	1,221
Profit Before Tax	61,498	50,873	42,796	38,195	34,318
Tax %	25%	25%	26%	29%	35%
Net Profit	46,149	38,151	31,857	27,296	22,446
EPS in Rs	83	69	58	50	42

Balance Sheet

Below figures are in Rs. Crores

Particulars	Mar-2026	Mar-2025	Mar-2024	Mar-2023	Mar-2022
Share Capital	383	255	255	255	255
Total Reserves	38,549	35,416	20,232	17,097	15,017
Long-Term Borrowings	---	---	---	---	---
Total Non-Current Liabilities	10,472	9,821	860	718	921
Other Current Liabilities	2,232	3,132	212	198	295
Short Term Borrowings	744	707	386	646	671
Total Liabilities	57,270	54,804	22,541	21,101	19,668
Capital Work in Progress	1,732	3,316	1,790	1,651	300
Long Term Loans & Advances	715	864	216	92	131
Currents Investments	2,663	1,917	7,739	4,189	4,812
Short Term Loans and Advances	1,853	1,918	520	2,332	2,060
Total Current Assets	17,963	17,582	12,532	11,554	12,652
Total Assets	57,270	54,804	22,541	21,101	19,668
Adjusted Book Value	102	140	80	68	60

Positive

(80 to 100)

Neutral

(60 to 79)

Negative

(0 to 59)

The stock has a high PE of 94.64, indicating expensive valuation or elevated growth expectations.
Over the last three years, the stock delivered a weak 3-year price CAGR of -5.1%, indicating poor shareholder returns.
The stock carries a beta of 0.8, indicating volatility broadly in line with the market.
In the last financial year, the company reported an EBITDA of ₹4611 million, reflecting positive operating performance.
In the previous financial year, the company generated revenue of ₹22686 million, indicating a large and established business.

Investment Calculator

Investment Amount:₹

Investment Amount: ₹ 1000000

Current Value: ₹ 447896.1

No. of Shares: 1010 (Approx)

Performance:-55.2%

-552103.9

NIFTY Performance: -6.2%

1 day Top Gainers